What are the NCCN and ATA guidelines on levothyroxine in the treatment of thyroid cancer?

Updated: Jun 24, 2020
  • Print
Answer

Answer

The ATA and NCCN guidelines recommend treatment with levothyroxine to suppress thyroid-stimulating hormone (TSH) levels. Degree of suppression is based on risk, as follows  [1, 5] :

  • Low-risk patients - Maintenance of the TSH at or slightly below the lower limit of normal (0.1 to 0.5 mU/L)
  • Intermediate-risk patients - Initial TSH suppression to below 0.1 mU/L
  • High-risk patients - Initial TSH suppression to below 0.1 mU/L

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!